Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval

Fineline Cube Nov 24, 2023

Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...

Company Deals

Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations

Fineline Cube Nov 24, 2023

Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly...

Company Drug

Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval...

Company Deals

True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development

Fineline Cube Nov 24, 2023

True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over...

Company Drug

MicuRx Pharmaceuticals Secures NMPA Approval for MRX-4 and Contezolid Combination Therapy

Fineline Cube Nov 24, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced that it has received clinical trial approval from...

Company Deals

Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China

Fineline Cube Nov 24, 2023

Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned...

Company Drug

C2 Pharma Secures C-DMF Approval for Pilocarpine Nitrate API

Fineline Cube Nov 24, 2023

Ireland-based C2 Pharma has announced the receipt of approval for a C-DMF (drug master file)...

Company Drug

SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...

Company Drug

Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study

Fineline Cube Nov 23, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...

Company Drug

RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China

Fineline Cube Nov 23, 2023

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...

Company Deals

Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio

Fineline Cube Nov 23, 2023

Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week,...

Company Drug Legal / IP

Bayer Halts Late-Stage Trial for Asundexian After Underperformance

Fineline Cube Nov 23, 2023

Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate...

Company Drug

Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...

Company Deals

Venus Medtech Partners with Valgen Holding on DragonFly Valve System

Fineline Cube Nov 23, 2023

China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen...

Company Deals

Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics

Fineline Cube Nov 23, 2023

Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of...

Company Drug

Sumitomo Pharma Receives Chinese Approval for Xenleta to Treat Pneumonia

Fineline Cube Nov 23, 2023

Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta...

Company Drug Medical Device

Gilead Announces Low-Carbon Bronchodilator Study for H1 2024

Fineline Cube Nov 23, 2023

Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA

Fineline Cube Nov 22, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

VivaVision Biotech Inc. Receives FDA Approval for VVN461 Phase II Clinical Trial

Fineline Cube Nov 22, 2023

China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food...

Posts pagination

1 … 461 462 463 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.